Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $359
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has maintained an Equal-Weight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raised the price target from $352 to $359.
October 09, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Vertex Pharmaceuticals and raised the price target from $352 to $359.
The raised price target by Morgan Stanley indicates a positive outlook for Vertex Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100